Disopyramide Sustained-Release Capsules and Isoptin SR

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using verapamil together with disopyramide may increase the risk of serious cardiovascular side effects such as excessively low blood pressure, fainting, heart failure, irregular heart rhythm, abnormally slow heart rate, and cardiac arrest. Close medical supervision is required if you are treated with this combination. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Concomitant use of disopyramide with other drugs that have negative inotropic effects such as verapamil may cause profound hypotension, syncope, bradycardia, asystole and heart failure, particularly in patients with conduction defects. Additionally, verapamil is a moderate CYP450 3A4 inhibitor and may interfere with the clearance of disopyramide. Increased exposure to disopyramide may potentiate the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death. Other adverse effects such as hypoglycemic coma and ventricular fibrillation may also occur.

MANAGEMENT: In general, concomitant use of disopyramide with verapamil should be avoided except in carefully selected patients (e.g., patients with symptomatic obstructive hypertrophic cardiomyopathy refractory to verapamil alone) who are under close medical supervision. The prescribing information for disopyramide and verapamil both recommend that disopyramide not be administered within 48 hours before or 24 hours after verapamil administration.

Disopyramide Sustained-Release Capsules

Generic Name: disopyramide

Brand name: Norpace, Norpace CR

Synonyms: Disopyramide

What is Disopyramide Sustained-Release Capsules?

Isoptin SR

Generic Name: verapamil

Brand name: Calan SR, Isoptin SR, Calan, Verelan, Isoptin, Isoptin IV, Covera-HS, Verelan PM

Synonyms: n.a.

What is Isoptin SR?